An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies.

Trial Profile

An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs TTP 607 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jul 2010 Planned end date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Jan 2010 Planned initiation date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top